Bone Biologics Corp (BBLGW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 400M 800M 1.2B Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q1 '20: 1.1B Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 1.1B Q2 '21: 0 Q1 '18 Q3 '18 Q1 '19 Q2 '20 Q4 '20 Q2 '21

Gross Profit Quarterly

0 Q3 '13: 0 Q3 '14: 0 Q3 '13 Q3 '14

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '16: -3.9M Q4 '16: -3.1M Q1 '17: -2.2M Q2 '17: 2M Q3 '17: -1.1M Q4 '17: -1.3M Q1 '18: -1.1M Q2 '18: -860.1K Q3 '18: 404.8K Q4 '18: -1.2M Q1 '19: -1.2M Q2 '19: -679.3K Q3 '19: -301.3K Q4 '19: -277.6K Q1 '20: -340.1K Q2 '20: -132.7K Q3 '20: -145.8K Q4 '20: -206.4K Q1 '21: -180.9K Q2 '21: -231.9K Q3 '21: -229.8K Q4 '21: -460.5K Q1 '22: -689.5K Q2 '22: -469.3K Q3 '22: -1.2M Q4 '22: -1.3M Q1 '23: -3.1M Q2 '23: -3M Q3 '23: -2.1M Q4 '23: -1.2M Q1 '24: -903.5K Q2 '24: -809.7K Q3 '24: -951K Q4 '24: -1.6M Q1 '25: -1M Q2 '25: -748.1K Q3 '25: -715.3K Q4 '25: -733.1K Q1 '26: -805.1K Q2 '26: -808.1K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '16: -4.4M Q4 '16: -4.7M Q1 '17: -2.9M Q2 '17: 1M Q3 '17: -2.4M Q4 '17: -2.8M Q1 '18: -1.5M Q2 '18: -1.3M Q3 '18: -241.7K Q4 '18: -1.5M Q1 '19: -1.4M Q2 '19: -925.6K Q3 '19: -561.4K Q4 '19: -531.1K Q1 '20: -596.9K Q2 '20: -380K Q3 '20: -394K Q4 '20: -453.7K Q1 '21: -431.7K Q2 '21: -491.9K Q3 '21: -509.3K Q4 '21: -177.7K Q1 '22: -689.5K Q2 '22: -469.3K Q3 '22: -1.2M Q4 '22: 893.5K Q1 '23: -3.7M Q2 '23: -1.8M Q3 '23: -1.9M Q4 '23: -1.5M Q1 '24: -866K Q2 '24: -783.7K Q3 '24: -941K Q4 '24: -1.5M Q1 '25: -1M Q2 '25: -740.5K Q3 '25: -666.7K Q4 '25: -684.6K Q1 '26: -766K Q2 '26: -773.7K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '16: -1.5M Q4 '16: -1.3M Q1 '17: -1M Q2 '17: -829.3K Q3 '17: -561K Q4 '17: -931.7K Q1 '18: -818.9K Q2 '18: -666.8K Q3 '18: -1.3M Q4 '18: -1.3M Q1 '19: -929K Q2 '19: -1.6M Q3 '19: -474.5K Q4 '19: -297.7K Q1 '20: -149.9K Q2 '20: -79.1K Q3 '20: -72.2K Q4 '20: -125.7K Q1 '21: -128K Q2 '21: -636K Q3 '21: -277.8K Q4 '21: -186.9K Q1 '22: -860.8K Q2 '22: -360.1K Q3 '22: -395.3K Q4 '22: -2M Q1 '23: -1.3M Q2 '23: -3.6M Q3 '23: -2.6M Q4 '23: -2M Q1 '24: -1.3M Q2 '24: -895.9K Q3 '24: -572.2K Q4 '24: -1.4M Q1 '25: -926.1K Q2 '25: -458.9K Q3 '25: -591.4K Q4 '25: -714.8K Q1 '26: -804.3K Q2 '26: -518.4K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q1 '15: -492.3K Q2 '15: -1M Q3 '15: -1M Q4 '15: -1M Q1 '15 Q2 '15 Q3 '15 Q4 '15

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '11: 5M Q3 '12: 5M Q2 '16: 38.2M Q2 '17: 4.1M Q2 '18: 4.4M Q1 '21: 2.9M Q2 '21: 2.9M Q3 '21: 2.9M Q1 '22: 10.4M Q2 '22: 345K Q3 '22: 345K Q1 '23: 67.2K Q2 '23: 339.3K Q3 '23: 391.9K Q1 '24: 660.9K Q2 '24: 194.8K Q3 '24: 292.3K Q1 '25: 530.6K Q2 '25: 557.8K Q3 '25: 1.8M Q1 '26: 1.8M Q2 '26: 1.8M Q3 '11 Q2 '17 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-105.00 -70.00 -35.00 0.00 35.00 70.00 105.00 Q2 '13: 0.00 Q3 '13: 0.00 Q2 '15: -0.31 Q3 '15: -0.22 Q4 '15: -0.49 Q1 '16: -0.62 Q2 '16: -0.72 Q3 '16: -0.72 Q4 '16: -0.56 Q1 '17: -0.44 Q2 '17: -0.06 Q3 '17: -0.56 Q4 '17: -2.14 Q1 '18: -2.39 Q2 '18: -2.93 Q3 '18: -2.35 Q4 '18: -0.98 Q1 '19: -0.84 Q2 '19: -0.68 Q3 '19: -0.73 Q4 '19: -0.47 Q1 '20: -0.36 Q2 '20: -0.28 Q3 '20: -0.34 Q4 '20: -0.43 Q1 '21: -0.41 Q2 '21: -0.43 Q3 '21: -0.46 Q4 '21: -0.35 Q1 '22: -0.36 Q2 '22: -1.65 Q3 '22: -5.01 Q4 '22: -29.22 Q1 '23: -84.35 Q2 '23: -88.20 Q3 '23: -89.57 Q3 '25: -3.49 Q4 '25: -2.65 Q1 '26: -1.16 Q2 '26: -0.26 Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.